New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 10, 2014
07:54 EDTZGNXZogenix weakness creates buying opportunity, says Oppenheimer
Oppenheimer believes that the recent weakness in Zogenix has been caused by media headlines that rehashed the controversy regarding the approval of its Zohydro drug, as well as a misunderstanding of the company's comments regarding its use of cash. The firm does not expect the FDA to reverse its approval of the drug, and it views the change in the company's Q4 EPS as a result of a non-cash charge as " an accounting artifact." The firm keeps a $5 price target and Outperform rating on the stock.
News For ZGNX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 5, 2015
16:28 EDTZGNXGreat Point raises passive stake in Zogenix to 5.93%
September 30, 2015
08:07 EDTZGNXZogenix reports positive top-line results from Relday Phase 1b clinical trial
Zogenix announced positive top-line pharmacokinetic results from its Phase 1b multi-dose clinical trial of Relday, a proprietary, once-monthly subcutaneous investigational formulation of risperidone for the treatment of schizophrenia. If approved, Relday has the potential to be the first subcutaneous antipsychotic product that achieves therapeutic drug levels on the first day of administration, allows for once-monthly dosing and does not require reconstitution. Zogenix has retained Locust Walk Partners of Cambridge, MA, a transaction advisory firm for life sciences companies, to provide transaction advisory and support services for Relday, and has now initiated efforts to secure a global strategic development and commercialization partner for Relday. The Phase 1b multi-dose parallel group clinical trial enrolled 60 subjects comprised of three cohorts of patients receiving four monthly injections of Relday, at dose levels of either 60, 90 or 120 mg of risperidone per month. A fourth cohort received five bi-weekly intramuscular injections of Risperdal Consta. Risperdal Consta requires oral supplementation for the first three weeks following dosing initiation, and requires at least four doses to reach steady state. The results for Relday demonstrated that risperidone plasma concentrations in the therapeutic range were achieved on the first day of dosing, reached steady state levels following the second dose and consistently maintained therapeutic levels throughout the four-month period. In addition, dose proportionality was confirmed across the dose range intended for clinical practice (60 to 120 mg). Relday was generally safe and well-tolerated, with results consistent with the profile of risperidone and the Company's previous Phase 1 single-dose clinical trial.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use